Skip to content

The effect of transversus abdominis plane block on intestinal edema in colorectal cancer patients: a randomized controlled trial

The effect of transversus abdominis plane block on intestinal edema in colorectal cancer patients: a randomized controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127572
Enrollment
Unknown
Registered
2026-07-02
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal edema

Interventions

TAP group (Transversus Abdominis Plane block group):Ultrasound-guided transversus abdominis plane block (TAP block): performed before anesthesia induction and surgical start, by trained anesthesiologi
Control group:Conventional anesthesia management (without TAP block): induction with dexmedetomidine, lidocaine, sufentanil, propofol, vecuronium
maintenance with sevoflurane, propofol, remifentanil, vecuronium
intraoperative management includes routine fluid administration (crystalloid-colloid ratio 2:1), prophylactic medications (palonosetron, dexamethasone, parecoxib sodium)

Sponsors

The First People’s Hospital of Lianyungang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective laparoscopic colorectal cancer surgery; 2. Age range: 18-80 years old; 3. Body Mass Index (BMI) 18-35kg/m^2; 4. American Society of Anesthesiologists (ASA) grades I-III; 5. Tolerant individuals to all relevant drugs in this study; 6. Those who voluntarily participate in this study and sign relevant informed consent forms.

Exclusion criteria

Exclusion criteria: 1. Cannot cooperate with nerve block patients; 2. Combining common diseases that cause intestinal edema (such as inflammatory bowel disease); 3. Patients with severe functional impairments in the heart, brain, kidneys, lungs, and liver, or other malignant tumor diseases; 4. Those who cannot understand the relevant rating scales.

Design outcomes

Primary

MeasureTime frame
Ratio of dry to wet weight of intestinal tissue specimens;

Secondary

MeasureTime frame
Thickness of intestinal wall in tissue specimens;Abundance of tight junction proteins in intestinal tissue specimens;Intraoperative fluid input and output;Heart rate and mean arterial pressure (MAP);Serum levels of tumor necrosis factor-alpha (TNF-a);Postoperative gastrointestinal function I-FEED score;Time to first flatus, defecation, and initiation of clear liquid diet after surgery;Patient satisfaction level;Visual analog scale (VAS) score;Surgical duration and anesthesia duration;Intraoperative blood loss, blood transfusion volume, fluid infusion volume, and urine output;Consumption of intraoperative drugs such as propofol, sufentanil, and remifentanil;Postoperative opioid consumption;Visual analog scale (VAS) scores recorded on postoperative days 1, 3, and 7;Length of hospital stay;Patient satisfaction;

Countries

China

Contacts

Public ContactFeng Jiyin

The First People’s Hospital of Lianyungang

fengjysd@163.com+86 518 85856782

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026